From Broad-Spectrum Research to Targeted Cure Programs

The medical research line includes one comprehensive research program and three disease-specific initiatives. Each product delivers research data, methodologies, and implementation resources for pharmaceutical companies, research hospitals, and government health agencies.

300 Disease Cure Research — $15,000,000

The flagship medical product at $15 million provides a broad-spectrum research package targeting cures for over 300 diseases. This dataset and methodology package is designed for large pharmaceutical companies and national health research agencies that need a systematic approach to multi-disease research.

Parkinson’s Cure Discovery — $5,000,000

A focused research package targeting Parkinson’s disease at $5 million. Includes specific research pathways, data models, and implementation guidance for organizations dedicated to neurodegenerative disease research.

Alzheimer’s Cure Discovery — $5,000,000

Targeted Alzheimer’s research at $5 million. Provides the data and methodologies needed to pursue cure development for the most prevalent form of dementia, a condition affecting tens of millions worldwide.

Diabetes Cure Discovery — $5,000,000

Diabetes-focused research at $5 million. Delivers cure research pathways for a condition that affects over 400 million people globally, with particular value for insulin manufacturers, endocrinology research centers, and national diabetes foundations.

Available Payment Options

Companies can pay via the structures below. Exact amounts and terms are set per item at agreement. Use the calculator to see approximate payments for a given total and term.

• One-Time Payment — At $5M per targeted program, a single payment is feasible for most pharmaceutical companies and well-funded research institutions.
• Royalty — 20–30% upfront plus a percentage of net revenue from resulting treatments. This aligns the cost with the commercial success of any cures developed from the research.
• Revenue Share — Percentage of drug sales or licensing revenue with minimal upfront payment. Reduces the barrier for smaller biotech firms to access the research.
• Installments — Spread over 3 to 60 months. A 12-month installment plan on the $15M comprehensive package equals $1.25M per month.
• Milestone-Based — Payments tied to research phases: signing, data delivery, first clinical application, and regulatory submission.
• Custom — Hybrid terms combining upfront payment with royalties on resulting products.

Explore all four medical research products and model payments at christophergabrielbrown.com/all-products.html.

Masonry view